Unnamed: 0,title,date,stock,sentiment
320283.0,CEL-SCI Q2 EPS $(0.250) Down From $(0.220) YoY,2020-05-11 08:09:00-04:00,CVM,neutral
320284.0,72 Biggest Movers From Yesterday,2020-05-05 04:29:00-04:00,CVM,neutral
320285.0,"CEL-SCI shares are trading higher after the company announced that its Phase 3 study has reached the reached required number of events to evaluate data for Multikine in the treatment of head and neck cancer. UPDATE: Shares have since reversed, now lower.",2020-05-04 09:41:00-04:00,CVM,negative
320286.0,CEL-SCI Says Pivotal Phase 3 Study Has Reached Required Number Of Events To Evaluate Data For Multikine In Treatment Of Head And Neck Cancer,2020-05-04 07:15:00-04:00,CVM,negative
320287.0,81 Biggest Movers From Friday,2020-04-27 05:33:00-04:00,CVM,neutral
320288.0,CEL-SCI Highlights Recent Data Review For Pivotal Phase 3 Head And Neck Cancer Study: Independent Data Monitoring Committee Agrees With Continuing Trial Without Change,2020-04-23 09:18:00-04:00,CVM,negative
320289.0,"Cel-Sci Increase The Size Of Offering To 630,500 Shares At $12.22 Per Share For A Total Gross Proceeds Of $7.7 Million",2020-03-24 13:59:00-04:00,CVM,positive
320290.0,CEL-SCI Raises Previously-Announced Bought Deal For ~630.5K Common Shares At $12.22/Share,2020-03-24 09:29:00-04:00,CVM,positive
320291.0,CEL-SCI Corp Files Preliminary Prospectus Supplement Related To Common Stock Offering; Size Undisclosed,2020-03-24 06:27:00-04:00,CVM,neutral
320292.0,108 Biggest Movers From Yesterday,2020-03-11 05:34:00-04:00,CVM,neutral
320293.0,'There is a lot of misinformation being spread about CVM and our work.  Remember that the last CVM short position was about 6.5 m shares and the stock borrow rate is about 45%...' -Cel-SCI Tweets,2020-03-10 14:43:00-04:00,CVM,neutral
320294.0,CEL-SCI shares are trading lower. Not seeing any news to justify the price action.,2020-03-10 12:01:00-04:00,CVM,neutral
320295.0,"CEL-SCI Shares Lower, Seeing Short Report On Stock Alleging Fraud",2020-03-09 14:49:00-04:00,CVM,negative
320296.0,CEL-SCI Corp shares are trading higher after the company initiated the development of a coronavirus immunotherapy candidate.,2020-03-09 08:37:00-04:00,CVM,positive
320297.0,CEL-SCI Initiates Development of Immunotherapy to Treat COVID-19 Coronavirus Infection,2020-03-09 07:55:00-04:00,CVM,positive
320298.0,108 Biggest Movers From Yesterday,2020-03-03 04:57:00-05:00,CVM,neutral
320300.0,95 Biggest Movers From Yesterday,2020-02-27 05:18:00-05:00,CVM,neutral
320301.0,UPDATE: CEL-SCI CEO Says Co. Believes It Is Nearing End Of Long Phase 3 Study For Cancer Treatment Candidate,2020-02-26 15:33:00-05:00,CVM,negative
320302.0,CEL-SCI CEO Sends Letter To Shareholders,2020-02-26 15:25:00-05:00,CVM,neutral
320303.0,CEL-SCI Shares Halted On Circuit Breaker,2020-02-26 14:42:00-05:00,CVM,positive
320304.0,CEL-SCI Q1 EPS $(0.16) Down From $0.02 YoY,2020-02-10 08:01:00-05:00,CVM,neutral
320305.0,85 Biggest Movers From Yesterday,2020-02-04 04:56:00-05:00,CVM,neutral
320306.0,70 Biggest Movers From Yesterday,2020-01-23 05:52:00-05:00,CVM,neutral
320307.0,46 Stocks Moving In Wednesday's Mid-Day Session,2020-01-22 12:05:00-05:00,CVM,neutral
320308.0,82 Biggest Movers From Yesterday,2020-01-22 04:18:00-05:00,CVM,neutral
320309.0,85 Biggest Movers From Yesterday,2020-01-14 04:52:00-05:00,CVM,neutral
320310.0,CEL-SCI shares are trading higher after H.C. Wainwright initiated coverage on the stock with a Buy rating and a price target of $18 per share.,2020-01-13 11:13:00-05:00,CVM,positive
320311.0,"H.C. Wainwright Initiates Coverage On CEL-SCI with Buy Rating, Announces $18 Price Target",2020-01-13 07:34:00-05:00,CVM,neutral
320312.0,Cel-Sci Corp Announces the Closing of Its $5.5 Million Underwritten Offering,2019-12-27 11:15:00-05:00,CVM,neutral
320313.0,51 Biggest Movers From Tuesday,2019-12-26 05:14:00-05:00,CVM,neutral
320314.0,Mid-Day Market Update: Gold Rises 1%; NewLink Genetics Shares Spike Higher,2019-12-24 11:50:00-05:00,CVM,positive
320315.0,33 Stocks Moving In Tuesday's Mid-Day Session,2019-12-24 11:34:00-05:00,CVM,neutral
320316.0,CEL-SCI shares are trading lower after the company announced a common stock offering of ~606K shares for $9.07 per share.,2019-12-24 08:56:00-05:00,CVM,positive
320317.0,20 Stocks Moving in Tuesday's Pre-Market Session,2019-12-24 08:05:00-05:00,CVM,neutral
320318.0,CEL-SCI Prices ~606K Share Common Stock Offering At $9.07/Share,2019-12-24 07:16:00-05:00,CVM,positive
320319.0,A Peek Into The Markets: US Stock Futures Edge Higher,2019-12-24 07:10:00-05:00,CVM,neutral
320320.0,"4 Stocks To Watch For December 24, 2019",2019-12-24 04:30:00-05:00,CVM,neutral
320321.0,"CEL-SCI Announces Common Stock Offering, Size Not Disclosed",2019-12-23 16:05:00-05:00,CVM,neutral
320322.0,26 Stocks Moving in Wednesday's Pre-Market Session,2019-12-18 07:58:00-05:00,CVM,neutral
320323.0,10 Stocks With At Least 30% Borrow Fees,2019-12-17 09:10:00-05:00,CVM,neutral
320324.0,CEL-SCI FY19 EPS $(0.71) Down From $(0.7) YoY,2019-12-16 16:16:00-05:00,CVM,neutral
320325.0,28 Stocks Moving in Monday's Pre-Market Session,2019-10-28 08:05:00-04:00,CVM,neutral
320326.0,'Cel-Sci is publicly upbeat about its cancer drug. Privately it's trying to sell stock' -STAT News' Adam Feuerstein,2019-10-24 14:17:00-04:00,CVM,negative
320327.0,42 Biggest Movers From Yesterday,2019-10-09 05:05:00-04:00,CVM,neutral
320328.0,50 Biggest Movers From Yesterday,2019-09-27 04:31:00-04:00,CVM,neutral
320329.0,CEL-SCI shares are trading lower after the company reported Q3 EPS down from last year.,2019-08-14 16:28:00-04:00,CVM,neutral
320330.0,CEL-SCI Q3 EPS $(0.37) Down From $(0.36) YoY,2019-08-14 16:25:00-04:00,CVM,neutral
320331.0,54 Biggest Movers From Yesterday,2019-07-30 05:00:00-04:00,CVM,neutral
320332.0,42 Stocks Moving In Monday's Mid-Day Session,2019-07-29 12:30:00-04:00,CVM,neutral
320333.0,CEL-SCI Highlights Scientific Review On Inflammatory Disease Therapies Published In 'International Immunopharmacology',2019-07-23 09:32:00-04:00,CVM,neutral
320334.0,52 Biggest Movers From Yesterday,2019-07-16 05:15:00-04:00,CVM,neutral
320335.0,42 Stocks Moving In Monday's Mid-Day Session,2019-07-15 12:47:00-04:00,CVM,neutral
320336.0,40 Biggest Movers From Friday,2019-07-15 05:47:00-04:00,CVM,neutral
320337.0,CEL-SCI Collaborators Presents Data For New Vaccine In The Treatment Of Rheumatoid Arthritis At The International Conference On Immunity And Immunochemistry Meeting,2019-07-08 09:02:00-04:00,CVM,neutral
320338.0,44 Biggest Movers From Yesterday,2019-07-03 05:24:00-04:00,CVM,neutral
320339.0,33 Stocks Moving In Tuesday's Mid-Day Session,2019-07-02 12:11:00-04:00,CVM,neutral
320340.0,44 Stocks Moving In Wednesday's Mid-Day Session,2019-06-26 12:17:00-04:00,CVM,neutral
320341.0,51 Biggest Movers From Yesterday,2019-06-26 05:53:00-04:00,CVM,neutral
320342.0,42 Stocks Moving In Tuesday's Mid-Day Session,2019-06-25 12:44:00-04:00,CVM,neutral
320343.0,60 Biggest Movers From Yesterday,2019-06-25 05:12:00-04:00,CVM,neutral
320344.0,40 Stocks Moving In Monday's Mid-Day Session,2019-06-24 12:35:00-04:00,CVM,neutral
320345.0,54 Biggest Movers From Yesterday,2019-06-21 04:56:00-04:00,CVM,neutral
320346.0,54 Biggest Movers From Yesterday,2019-06-14 05:02:00-04:00,CVM,neutral
320347.0,The Companies Set To Join The Russell Index July 1,2019-06-11 16:35:00-04:00,CVM,positive
320348.0,52 Biggest Movers From Yesterday,2019-06-11 04:43:00-04:00,CVM,neutral
320349.0,"CEL-SCI Shares Spike Higher Above $5.50 Level, Now Up 27.5% For Session; Co. Earlier Announced It Will Join Russell 3000 Index On July 1, 2019",2019-06-10 10:50:00-04:00,CVM,positive
320350.0,54 Biggest Movers From Yesterday,2019-06-05 06:14:00-04:00,CVM,neutral
320351.0,Shares of several small-cap companies are trading higher on continued volatility as the whole US market rebounded following eased world trade tensions.,2019-06-04 14:22:00-04:00,CVM,positive
320352.0,44 Stocks Moving In Tuesday's Mid-Day Session,2019-06-04 12:44:00-04:00,CVM,neutral
320353.0,"Companies Which Will Be Presenting At LD Micro's 9th Annual Micro Invitational Tues., Jun. 4, 2019",2019-06-03 16:57:00-04:00,CVM,neutral
320354.0,'Setting The Record Straight On CEL-SCI' -Earlier Seeking Alpha Blogpost From CVM4Life,2019-05-29 11:16:00-04:00,CVM,positive
320355.0,30 Stocks Moving In Friday's Mid-Day Session,2019-05-24 13:00:00-04:00,CVM,neutral
320356.0,60 Biggest Movers From Friday,2019-05-20 05:06:00-04:00,CVM,neutral
320357.0,44 Stocks Moving In Friday's Mid-Day Session,2019-05-17 12:26:00-04:00,CVM,neutral
320358.0,63 Biggest Movers From Yesterday,2019-05-17 05:05:00-04:00,CVM,neutral
320359.0,CEL-SCI Q2 EPS $(0.22) Up From $(0.31) YoY,2019-05-14 16:20:00-04:00,CVM,neutral
320360.0,CEL-SCI Presents New Data for Its LEAPS Vaccine in the Treatment of Rheumatoid Arthritis at the American Association of Immunologists 103rd Annual Meeting,2019-05-13 09:02:00-04:00,CVM,neutral
320361.0,CEL-SCI CEO Issues Letter To Shareholders,2019-05-08 08:11:00-04:00,CVM,neutral
320362.0,Streetsweeper Issued Negative Report On CEL-SCI Corp,2019-04-24 10:30:00-04:00,CVM,negative
320363.0,40 Biggest Movers From Yesterday,2019-04-17 07:26:00-04:00,CVM,neutral
320364.0,38 Stocks Moving In Tuesday's Mid-Day Session,2019-04-09 12:52:00-04:00,CVM,neutral
320365.0,50 Biggest Movers From Yesterday,2019-04-09 06:48:00-04:00,CVM,neutral
320366.0,54 Biggest Movers From Friday,2019-04-08 05:11:00-04:00,CVM,neutral
320367.0,58 Biggest Movers From Yesterday,2019-04-02 05:45:00-04:00,CVM,neutral
320368.0,46 Stocks Moving In Monday's Mid-Day Session,2019-04-01 13:06:00-04:00,CVM,neutral
320369.0,62 Biggest Movers From Friday,2019-04-01 04:46:00-04:00,CVM,neutral
320370.0,CEL-SCI Highlights Recent Data Review By Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study: Recommended Continue Trial Until Appropriate Number Of Events Have Occurred,2019-03-29 09:01:00-04:00,CVM,negative
320371.0,CEL-SCI Announces Extension of its Phase 3 Trial in a Letter to Shareholders,2019-03-25 08:15:00-04:00,CVM,neutral
320372.0,CEL-SCI Selected By National Institutes of Health To Showcase Its LEAPS Technology At BIO International Convention,2019-03-07 11:00:00-05:00,CVM,neutral
320373.0,"CEL-SCI Q1 EPS $0.02 Up From $(0.53) YoY, Sales $126.41K Up From $113.897K YoY",2019-02-14 16:39:00-05:00,CVM,neutral
320374.0,CEL-SCI Shares Spike To Session High; Traders Circulating Word Zacks Initiated Stock With A Buy Rating And $14 Price Target; BZ NOTE: Zacks Research Does Not Normally Move Stocks,2019-01-31 11:10:00-05:00,CVM,positive
320375.0,55 Biggest Movers From Yesterday,2019-01-16 05:12:00-05:00,CVM,neutral
320376.0,CEL-SCI Reports Regained Full Compliance With NYSE American,2019-01-15 08:08:00-05:00,CVM,neutral
320377.0,CEL-SCI FY18 EPS $(1.87) vs $(1.91) In FY17,2018-12-20 09:03:00-05:00,CVM,neutral
320378.0,36 Biggest Movers From Friday,2018-11-26 05:26:00-05:00,CVM,neutral
320379.0,35 Stocks Moving In Friday's Mid-Day Session,2018-11-23 12:25:00-05:00,CVM,neutral
320380.0,56 Biggest Movers From Yesterday,2018-10-24 05:53:00-04:00,CVM,neutral
320381.0,44 Stocks Moving In Tuesday's Mid-Day Session,2018-10-23 13:05:00-04:00,CVM,neutral
320382.0,CEL-SCI Recieves $8M Through Warrant Exercises,2018-10-23 08:33:00-04:00,CVM,neutral
320383.0,28 Stocks Moving In Monday's Pre-Market Session,2018-09-17 08:02:00-04:00,CVM,neutral
320384.0,44 Biggest Movers From Friday,2018-09-17 05:10:00-04:00,CVM,neutral
320385.0,32 Stocks Moving In Friday's Mid-Day Session,2018-09-14 12:31:00-04:00,CVM,neutral
320386.0,CEL-SCI shares are trading up 14.1% after the company received $5.4 million from warrant exercises.,2018-09-14 11:17:00-04:00,CVM,positive
320387.0,CEL-SCI Receives $5.4M from Warrant Exercises,2018-09-14 09:03:00-04:00,CVM,neutral
320388.0,CEL-SCI Wins $5.4M From Warrant Exercises,2018-09-14 09:01:00-04:00,CVM,positive
320389.0,46 Biggest Movers From Yesterday,2018-09-14 04:40:00-04:00,CVM,neutral
320390.0,"Stocks That Made New 52-Week Highs Yesterday, September 6th",2018-09-07 16:47:00-04:00,CVM,neutral
320391.0,55 Biggest Movers From Yesterday,2018-09-07 05:17:00-04:00,CVM,neutral
320392.0,40 Stocks Moving In Thursday's Mid-Day Session,2018-09-06 12:31:00-04:00,CVM,neutral
320393.0,"CEL-SCI shares are up 15.9%, continuing to spike after the company on Wednesday announced its rheumatoid arthritis vaccine was selected by  National Institutes Of Health (NIH) for a commercialization acceleration program.",2018-09-06 10:46:00-04:00,CVM,positive
320394.0,CEL-SCI's LEAPS Rheumatoid Arthritis Vaccine Selected By National Institutes Of Health (NIH) For Commercialization Accelerator Program,2018-09-05 09:05:00-04:00,CVM,neutral
320395.0,44 Biggest Movers From Friday,2018-09-04 05:33:00-04:00,CVM,neutral
320396.0,33 Stocks Moving In Friday's Mid-Day Session,2018-08-31 12:34:00-04:00,CVM,neutral
320397.0,Cel-Sci 8-K Shows Co. Agreed To Issue Ergomed 1M Restricted Shares Of Co. Common Stock In Payment Of Amount Co. Indebted To Ergomed For Services Related To Phase III Trial,2018-08-31 11:03:00-04:00,CVM,positive
320398.0,26 Stocks Moving In Friday's Pre-Market Session,2018-08-31 08:08:00-04:00,CVM,neutral
320399.0,62 Biggest Movers From Yesterday,2018-08-31 05:19:00-04:00,CVM,neutral
320400.0,45 Biggest Movers From Yesterday,2018-08-30 05:38:00-04:00,CVM,neutral
320401.0,CEL-SCI Corporation Releases Letter to Shareholders,2018-08-21 10:02:00-04:00,CVM,neutral
320402.0,CEL-SCI Reports Recent Data Review By Independent Data Monitoring Committee For Phase 3 Head and Neck Cancer Study; Independent Data Monitoring Committee Recommends Continuation Of Trial Until Appropriate Number Of Events Have Occurred,2018-08-15 08:33:00-04:00,CVM,negative
320403.0,CEL-SCI Q3 EPS $(0.36) Up From $(0.53) YoY,2018-08-14 16:33:00-04:00,CVM,neutral
320404.0,"Stocks Which Set New 52-Week Low Yesterday, August 8th",2018-08-09 11:10:00-04:00,CVM,negative
320405.0,"Stocks Which Set New 52-Week Low Yesterday, August 7th",2018-08-08 11:06:00-04:00,CVM,negative
320406.0,CEL-SCI S-3 Shows Registration For $100M Common Stock Offering,2018-08-03 12:20:00-04:00,CVM,neutral
320407.0,Cavium Resumes Trade Now Down 26% At $1.20/Share,2018-06-28 13:31:00-04:00,CVM,neutral
320408.0,"CEL-SCI Announces $5M Registered Direct Offering, Will Issue 3.9M Shares At Price Of $1.30/Share",2018-06-28 13:10:00-04:00,CVM,positive
320409.0,CEL-SCI Halted News Pending,2018-06-28 13:07:00-04:00,CVM,neutral
320410.0,42 Biggest Movers From Yesterday,2018-06-28 05:44:00-04:00,CVM,neutral
320411.0,40 Stocks Moving In Wednesday's Mid-Day Session,2018-06-27 13:04:00-04:00,CVM,neutral
320412.0,CEL-SCI Shares Now Down 30%,2018-06-27 08:36:00-04:00,CVM,positive
320413.0,"CEL-SCI Shares Reverse: Initially Traded Up 3%, Now Down 10.5%",2018-06-27 08:27:00-04:00,CVM,positive
320414.0,"CEL-SCI Shares Resume Trade, Now Up 3.9%",2018-06-27 08:18:00-04:00,CVM,positive
320415.0,"UPDATE: CEL-SCI Says Ruling Showed inVentiv Materially Breached Contract, Knowingly Misled Co. Related To Enrollment Projections",2018-06-27 08:03:00-04:00,CVM,neutral
320416.0,CEL-SCI Reports Winning Of Breach Of Contract Ruling Against inVentive/Syneos Health,2018-06-27 08:02:00-04:00,CVM,positive
320417.0,CEL-SCI Shares Halted News Pending,2018-06-27 07:37:00-04:00,CVM,positive
320418.0,54 Biggest Movers From Yesterday,2018-06-27 04:51:00-04:00,CVM,neutral
320419.0,CEL-SCI Issues Letter To Holders,2018-06-11 09:03:00-04:00,CVM,neutral
320420.0,U.S. Patent Office Allows Two New CEL-SCI Patents For LEAPS Vaccine Platform Technology,2018-06-08 08:31:00-04:00,CVM,neutral
320421.0,25 Stocks Moving In Thursday's Pre-Market Session,2018-05-24 08:40:00-04:00,CVM,neutral
320422.0,CEL-SCI Q2 EPS $(0.81),2018-05-15 16:42:00-04:00,CVM,neutral
320423.0,31 Biggest Movers From Yesterday,2018-05-08 05:12:00-04:00,CVM,neutral
320424.0,26 Stocks Moving In Monday's Pre-Market Session,2018-04-30 08:07:00-04:00,CVM,neutral
320425.0,46 Biggest Movers From Friday,2018-04-30 06:12:00-04:00,CVM,neutral
320426.0,CEL-SCI Corporation Issues Letter to Shareholders,2018-04-04 08:00:00-04:00,CVM,neutral
320427.0,"BIO CEO & Investor Conference Concludes Today, With CEL-SCI, Cue Biopharma, and Biotime Among Those Attending",2018-02-13 06:02:00-05:00,CVM,neutral
320428.0,"CEL-SCI Reports Q1 EPS $(0.53) vs $0.32 In Same Qtr. Last Year, Grant Income $113.897K vs $17.258K YoY",2018-02-12 17:21:00-05:00,CVM,positive
320429.0,CEL-SCI Reports US Patent Office Allowed New Co. Patent For LEAPS Vaccine Platform Technology,2018-01-30 10:01:00-05:00,CVM,neutral
320430.0,CEL-SCI Announces Change To Warrant Exercise Price Of Series S Warrants Listed Under 'CVM WS',2018-01-16 08:17:00-05:00,CVM,neutral
320431.0,UPDATE: CEL-SCI Says 'LEAPS Platform Technology is currently being developed as a therapeutic vaccine for rheumatoid arthritis with support of a NIAMS grant of the NIH',2018-01-08 07:51:00-05:00,CVM,positive
320432.0,CEL-SCI Reports Winning Of Patent For LEAPS Vaccine In Treatment Of RA,2018-01-08 07:51:00-05:00,CVM,positive
320433.0,CEL-SCI Issues Letter to Shareholders,2018-01-03 07:31:00-05:00,CVM,neutral
320434.0,"5 Stocks To Watch For January 2, 2018",2018-01-02 04:30:00-05:00,CVM,neutral
320435.0,CEL-SCI Reports FY17 EPS $(1.91) vs $(2.37) In '16,2017-12-29 16:18:00-05:00,CVM,neutral
320436.0,CEL-SCI Reports Reached Full Enrollment In Phase 3 Head And Neck Cancer Study,2017-12-11 13:35:00-05:00,CVM,negative
320437.0,"CEL-SCI Reports IDMC Saw No evidence Of Any Significant Safety Questions, Recommends Continuing Study In Its Phase 3 Head and Neck Cancer Study",2017-12-07 07:34:00-05:00,CVM,negative
320438.0,CEL-SCI Granted European Patent for Multikine's Mechanism of Action,2017-10-10 08:30:00-04:00,CVM,positive
320439.0,CEL-SCI Reports $1.5M NIH SBIR Grant to Support Development of Rheumatoid Arthritis Vaccine,2017-09-19 09:03:00-04:00,CVM,positive
320440.0,Sabby Management Reports 7.4% Stake In CEL-SCI Corp.,2017-08-23 12:49:00-04:00,CVM,neutral
320441.0,15 Biggest Mid-Day Losers For Wednesday,2017-08-23 12:42:00-04:00,CVM,negative
320442.0,CEL-SCI Reports $3.5M Registered Direct Offering,2017-08-23 09:01:00-04:00,CVM,neutral
320443.0,Mid-Afternoon Market Update: Crude Oil Down 2%; Neff Shares Spike Higher,2017-08-14 14:30:00-04:00,CVM,negative
320444.0,15 Biggest Mid-Day Gainers For Monday,2017-08-14 12:42:00-04:00,CVM,neutral
320445.0,Mid-Day Market Update: Sorl Auto Parts Drops After Q2 Results; CEL-SCI Shares Surge,2017-08-14 12:04:00-04:00,CVM,positive
320446.0,Mid-Morning Market Update: Markets Open Higher; VF Corp To Buy Williamson-Dickie,2017-08-14 10:14:00-04:00,CVM,neutral
320447.0,CEL-SCI's Phase 3 Head & Neck Cancer Trial's Clinical Hold Removed by the FDA,2017-08-14 07:02:00-04:00,CVM,negative
320448.0,CEL-SCI Reports Q3 Loss/Share $(0.53) vs. $(0.78) In Same Qtr. Last Year,2017-08-09 16:33:00-04:00,CVM,neutral
320449.0,10 Biggest Mid-Day Gainers For Monday,2017-07-03 12:21:00-04:00,CVM,neutral
320450.0,CEL-SCI Shares Halted News Pending,2017-06-22 10:10:00-04:00,CVM,positive
320451.0,Mid-Afternoon Market Update: Cheesecake Factory Slides After Lower Guidance; Cleantech Solutions Shares Gain,2017-06-13 14:33:00-04:00,CVM,positive
320452.0,12 Biggest Mid-Day Losers For Tuesday,2017-06-13 13:05:00-04:00,CVM,negative
320453.0,Mid-Day Market Update: Cavco Rises After Q4 Results; CEL-SCI Shares Plunge,2017-06-13 12:23:00-04:00,CVM,positive
320454.0,Mid-Morning Market Update: Markets Open Higher; John Wiley Reports Strong Q4 Results,2017-06-13 10:10:00-04:00,CVM,positive
320455.0,25 Stocks Moving In Tuesday's Pre-Market Session,2017-06-13 08:10:00-04:00,CVM,neutral
320456.0,CEL-SCI Reports 1-For-25 Reverse Split,2017-06-12 16:01:00-04:00,CVM,neutral
320457.0,CEL-SCI Reports New Data for Its Rheumatoid Arthritis Vaccine Candidate Published in Peer Reviewed Journal,2017-06-08 07:31:00-04:00,CVM,neutral
320458.0,CEL-SCI Submits FDA Response for Phase 3 Head and Neck Cancer Trial,2017-06-05 08:04:00-04:00,CVM,negative
320459.0,"CEL-SCI Issues Letter to Holders, Offers Update on Clinical Hold Communications with FDA",2017-05-24 07:08:00-04:00,CVM,neutral
320460.0,CEL-SCI Reports Q2 EPS $(0.05) vs $(0.07) in Same Qtr. Last Year,2017-05-10 16:31:00-04:00,CVM,neutral
320461.0,CEL-SCI Announces $1.51M Direct Offering,2017-05-01 08:42:00-04:00,CVM,neutral
320462.0,CEL-SCI Corporation Releases Letter to Shareholders Saying They Are Working With FDA To Have Partial Clinical Hold Lifted,2017-04-24 08:04:00-04:00,CVM,neutral
320463.0,CEL-SCI Reports $1.5M Registered Direct Offering,2017-03-09 08:00:00-05:00,CVM,neutral
320464.0,"UPDATE: CEL-SCI Says Will Provide List of Major Protocol Deviations, Plan to Identify Major Protocol Deviations Across All Patients",2017-03-06 08:05:00-05:00,CVM,neutral
320465.0,"CEL-SCI Offers Update on Partial Clinical Hold of Phase 3 Head and Neck Cancer Study with Multikine: Will Provide Updated Investigator's Brochure, Current Procedures for Compliance",2017-03-06 08:04:00-05:00,CVM,negative
320466.0,"CEL-SCI Reports $1.0 Million Registered Direct Offering, Will Issue $10M Shares At $0.10/Share",2017-02-17 08:30:00-05:00,CVM,positive
320467.0,UPDATE: Cel-Sci Says Has 'Immediately Begun Working on Those Steps' to Lift Partial Clinical Hold,2017-02-13 15:44:00-05:00,CVM,neutral
320468.0,8-K from Cel-Sci Shows Co. Met with FDA Feb. 8 to Discuss Steps Required to Lift Partial Clinical Hold,2017-02-13 15:43:00-05:00,CVM,neutral
320469.0,CEL-SCI Reports Q1 EPS $0.02 vs. Prior Year Quarter $0.02,2017-02-09 17:17:00-05:00,CVM,neutral
320470.0,12 Biggest Mid-Day Losers For Friday,2016-12-23 12:56:00-05:00,CVM,negative
320471.0,"UPDATE: CEL-SCI Says If Partial Hold is Not Lifted, Phase 3 Study Will Not Be Able to Be Completed to Its Prespecified Endpoints in Timely Manner",2016-12-22 17:14:00-05:00,CVM,neutral
320472.0,UPDATE: CEL-SCI Says Will Not Be Able to Enroll Added Patients in Phase 3 Study Unless FDA Lifts Partial Hold,2016-12-22 17:13:00-05:00,CVM,neutral
320473.0,"UPDATE: CEL-SCI Says, Subject to Partial Clinical Hold, Sees Total Remaining Cash Cost of Phase 3 Trial ~$12M",2016-12-22 17:13:00-05:00,CVM,neutral
320474.0,UPDATE: CEL-SCI Says Reviewing All Options In Response to FDA's Incomplete Response to Hold Letter,2016-12-22 17:12:00-05:00,CVM,neutral
320475.0,UPDATE: CEL-SCI Says FDA Identified 4 Deficiencies Related to Clinical Hold Letter,2016-12-22 17:11:00-05:00,CVM,neutral
320476.0,"8-K from CEL-SCI Shows FDA, on Dec. 16, Issued Incomplete Response to Hold Letter",2016-12-22 17:10:00-05:00,CVM,neutral
320477.0,Mid-Afternoon Market Update: Crude Oil Up 1%; Five Below Shares Rise On Earnings Beat,2016-12-02 14:26:00-05:00,CVM,negative
320478.0,15 Biggest Mid-Day Losers For Friday,2016-12-02 13:31:00-05:00,CVM,negative
320479.0,Mid-Day Market Update: Smith & Wesson Declines On Weak Forecast; Envision Healthcare Shares Spike Higher,2016-12-02 12:15:00-05:00,CVM,negative
320480.0,Mid-Morning Market Update: Markets Mixed; Big Lots Earnings Beat Estimates,2016-12-02 09:50:00-05:00,CVM,neutral
320481.0,25 Stocks Moving In Friday's Pre-Market Session,2016-12-02 08:26:00-05:00,CVM,neutral
320482.0,"CEL-SCI Announces Pricing of $4.25 Million Public Offering of Common Stock and Warrants, Prices 34.02M Shares Of Stock & Warrants At $0.125/Share",2016-12-02 07:00:00-05:00,CVM,positive
320483.0,CEL-SCI Announces Proposed Public Offering of Common Stock and Warrants,2016-12-01 16:04:00-05:00,CVM,neutral
320484.0,CEL-SCI Submits Response to FDA in Connection with Partial Clinical Hold on Phase 3 Clinical Trial,2016-11-21 08:31:00-05:00,CVM,neutral
320485.0,"CEL-Sci Reports Preclinical Data Showing LEAPS Vaccine is Successful in Treating RA, Suppresses Arthritis Severity, Limits Joint Damage",2016-11-14 09:01:00-05:00,CVM,positive
320486.0,TheStreet's Adam Feuerstein Tweets '$CVM refuses to disclose any details about FDA's partial clinical hold on ph3 trial. It's past due for SEC to crack down on BS like this.',2016-10-21 08:38:00-04:00,CVM,positive
320487.0,Adam Feuerstein Tweets: $CVM refuses to disclose any details about FDA's partial clinical hold on ph3 trial. It's past due for SEC to crack down on BS like this.,2016-10-21 08:34:00-04:00,CVM,positive
320488.0,CEL-SCI Says Has Started Working on Response to FDA's Partial Clinical Hold Issued Sept. 26,2016-10-21 08:01:00-04:00,CVM,neutral
320489.0,CEL-SCI Announces FDA Places Clinical Hold on Head and Neck Cancer Study,2016-09-27 04:31:00-04:00,CVM,negative
320490.0,CEL-SCI Announces Chairmain and Founder Maximilian de Clara Resigning for Health Reasons,2016-09-06 08:35:00-04:00,CVM,negative
320491.0,CEL-SCI Reports $5M Registered Direct Offering,2016-08-23 09:00:00-04:00,CVM,neutral
320492.0,CEL-SCI Reports Q3 EPS $(0.03) vs $(0.06) in the Same Qtr. Last Year,2016-08-10 08:05:00-04:00,CVM,neutral
320493.0,CEL-SCI Reports Monthly Patient Enrollment in July for Its Phase 3 Head and Neck Cancer Trial,2016-08-01 09:00:00-04:00,CVM,negative
320494.0,CEL-SCI Granted European Patent for Multikine Cancer Immunotherapy in Combination with Radiation and/or Chemotherapy,2016-07-11 08:01:00-04:00,CVM,negative
320495.0,CEL-SCI Reports Enrolled 19 Patients in Ongoing Phase 3 Trial of Multikine; Total Enrollment 816,2016-06-01 08:15:00-04:00,CVM,neutral
320496.0,Sabby Management Reports 6.9% Stake in Cel Sci in 13G,2016-05-24 06:19:00-04:00,CVM,neutral
320497.0,Cel-Sci Announces $5M Registered Direct Offering,2016-05-18 09:12:00-04:00,CVM,neutral
320498.0,CEL-SCI Reports Q2 EPS $(0.07) vs $(0.17) Est.,2016-05-10 16:42:00-04:00,CVM,neutral
320499.0,CEL-SCI Reports Record Monthly Patient Enrollment Of 41 Patients in April for Its Phase 3 Head and Neck Cancer Trial,2016-05-02 08:06:00-04:00,CVM,negative
320500.0,"CEL-SCI Reports Monthly Patient Enrollment in March for Its Phase 3 Head and Neck Cancer Trial, Enrolls 32 Patients",2016-04-01 08:14:00-04:00,CVM,negative
320501.0,"CEL-SCI Offers Monthly Patient Enrollment in Feb for Phase 3 Head, Neck Cancer Trial: Enrolled 27 Patients, Total Patient Enrollment Now 724",2016-03-01 09:01:00-05:00,CVM,negative
320502.0,CEL-SCI Corp. Reports Q1 EPS $0.02 vs. Prior Year Quarter $(0.11),2016-02-09 16:23:00-05:00,CVM,neutral
320503.0,"CEL-SCi Reports Patient Enrollment For Phase 3 Head, Neck Cancer Treatment In Jan.",2016-02-01 10:03:00-05:00,CVM,negative
320504.0,UPDATE: CEL-SCI Announces '15 Study Enrollment Exceeds Study Enrollment of All 4 Prior Years Combined,2016-01-05 08:04:00-05:00,CVM,neutral
320505.0,UPDATE: CEL-SCI Reports Record Year for Patient Enrollment with 75% Increase in Its Global Phase 3 Head and Neck Cancer Trial,2016-01-05 08:04:00-05:00,CVM,negative
320506.0,"CEL-SCI Reports Patient Enrollment Up 75% in Global Phase 3 Head, Neck Cancer Trial",2016-01-05 08:03:00-05:00,CVM,negative
320507.0,"CEL-SCI Offers Monthly Patient Enrollment in Nov. for Phase 3 Head, Neck Cancer Trial",2015-12-01 10:30:00-05:00,CVM,negative
320508.0,CEL-SCI's Rheumatoid Arthritis Vaccine Selected for Commercialization & Program Niche Analysis Plan by U.S. National Institutes of Health,2015-11-04 10:04:00-05:00,CVM,neutral
320509.0,CEL-SCI Reports Record Monthly Patient Enrollment in October for Its Phase 3 Head and Neck Cancer Trial,2015-11-02 08:15:00-05:00,CVM,negative
320510.0,"CEL-SCI Prices $12M Offering Of Stock, Warrants At $0.67/Unit",2015-10-23 08:40:00-04:00,CVM,neutral
320511.0,CEL-SCI Corporation Letter to Shareholders,2015-10-19 09:01:00-04:00,CVM,neutral
320512.0,"CEL-SCI Reports Ergomed Raises Co-Development Contribution Up to $12M in Co.'s Phase 3 Head, Neck Cancer Trial",2015-10-05 08:00:00-04:00,CVM,negative
320513.0,CEL-SCI Reports September Patient Enrollment for Its Phase 3 Head and Neck Cancer Trial,2015-10-01 08:32:00-04:00,CVM,negative
320514.0,CEL-SCI Reports August Patient Enrollment for Its Phase 3 Head and Neck Cancer Trial,2015-09-01 16:30:00-04:00,CVM,negative
320515.0,CEL-SCI Expands Its Phase I Study for Treatment of Anal Warts in HIV/HPV Co-Infected Patients with Addition of 2nd Site at University of California San Francisco,2015-07-20 08:32:00-04:00,CVM,positive
320516.0,S-3 from CEL SCI Corp. Shows Registration for $75M Mixed Securities Shelf Offering,2015-07-02 08:28:00-04:00,CVM,positive
320517.0,CEL-SCI Reports June Patient Enrollment in Its Phase 3 Head and Neck Cancer Trial,2015-07-01 09:20:00-04:00,CVM,negative
320518.0,CEL-SCI Reports Clearance to Start Patient Enrollment in Phase 3 Cancer Immunotherapy Trial in Thailand,2015-06-08 09:01:00-04:00,CVM,negative
320519.0,CEL-SCI Prices 16M Shares Ar $0.79/Unit,2015-05-22 09:05:00-04:00,CVM,positive
320520.0,Adam Feuerstein @adamfeuerstein Tweet: $CVM — Source tells me FBR scuttled offering due to inappropriate CEO meddling. That's why Dawson James brought on to salvage something.,2015-05-22 08:18:00-04:00,CVM,neutral
320521.0,CEL-SCI Announces Proposed Public Offering of Common Stock and Warrants,2015-05-21 16:33:00-04:00,CVM,neutral
320522.0,CEL-SCI Reports Authorization to Conduct Phase 3 Multikine Trial in Italy,2015-05-13 09:03:00-04:00,CVM,neutral
320523.0,CEL-SCI Granted Authorization to Begin Its Phase 3 Multikine Trial in Spain,2015-05-11 08:01:00-04:00,CVM,positive
320524.0,CEL-SCI Prices $35M Offering,2015-05-06 06:05:00-04:00,CVM,neutral
320525.0,CEL-SCI Corp. ANnounces Aintree University In UK To Be Clinical Site For Phase III Head and Neck Cancer Trial,2015-04-13 08:42:00-04:00,CVM,negative
320526.0,"CEL-SCI Reports Third Consecutive Month of Record Patient Enrollment in '15 for Phase III Head, Neck Cancer Trial",2015-04-01 08:48:00-04:00,CVM,negative
320527.0,CEL-SCI Reports 2nd Consecutive Month of Record Patient Enrollment in 2015 for Its Phase III Head and Neck Cancer Trial,2015-03-03 08:15:00-05:00,CVM,negative
320528.0,CEL-SCI Receives Clearance to Conduct Phase III Trial In 21 Countries,2015-02-27 15:25:00-05:00,CVM,neutral
320529.0,"CEL-SCI Announces Phase III Trial Enrollment for Head, Neck Cancer Trial Cleared in Philippines",2015-02-11 08:06:00-05:00,CVM,negative
320530.0,CEL-SCI Corporation Reports First Quarter EPS of $(0.11); Sees Phase 1 Trial Of Multikine Complete In Second half Of 2015,2015-02-06 16:42:00-05:00,CVM,neutral
320531.0,CEL-SCI Reports Record Monthly Patient Enrollment In Phase III Head and Neck Cancer Trial,2015-02-02 08:32:00-05:00,CVM,negative
320532.0,CEL-SCI Receives Regulatory Clearance to Expand Its Phase III Head and Neck Cancer Trial into Romania,2015-01-26 09:00:00-05:00,CVM,negative
320533.0,"CEL-SCI's 2014 Patient Enrollment Increases Significantly In 2013 In Its Phase III Head, Neck Cancer Trial",2015-01-05 08:32:00-05:00,CVM,negative
320534.0,CEL-SCI Reports FY EPS of $(0.49),2014-12-23 16:32:00-05:00,CVM,neutral
320535.0,CEL-SCI Expands Its Pivotal Phase III Immunotherapy Head and Neck Cancer Trial With Addition of 7 More Clinical Sites,2014-12-08 08:45:00-05:00,CVM,negative
320536.0,CEL-SCI Quarterly Patient Enrollment In Its Head And Neck Cancer Phase III Trial Increases Eight Fold Over Same Prior Year Period,2014-12-02 08:31:00-05:00,CVM,negative
320537.0,"CEL-SCI Quarterly Patient Enrollment In Its Head, Neck Cancer Phase III Trial Increases Eight Fold Over Same Prior Year Period",2014-12-02 08:31:00-05:00,CVM,negative
320538.0,CEL-SCI Enrolls 22 Patients During October In Its Phase III Immunotherapy Head And Neck Cancer Trial,2014-11-03 08:33:00-05:00,CVM,negative
320539.0,CEL-SCI Corporation Prices $6M Public Offering of Common Stock and Warrants; Combined Price Of $0.76 ,2014-10-21 09:55:00-04:00,CVM,neutral
320540.0,"CEL-SCI Reports Offering of Common Stock, Warrants",2014-10-20 16:39:00-04:00,CVM,neutral
320541.0,"CEL-SCI Reports Enrollment of 16 Patients in Phase III Imunotherapy Head, Neck Cancer Trial in Sept.",2014-10-03 09:16:00-04:00,CVM,negative
320542.0,CEL-SCI Reports Q3 Loss of $0.11/Share vs Loss of $0.18/Share in Same Qtr. Last Year,2014-08-08 16:18:00-04:00,CVM,negative
320543.0,CEL-SCI Announces 232 Patients Enrolled in Phase II Head and Neck Cancer Trial,2014-08-01 08:46:00-04:00,CVM,negative
320544.0,"CEL-SCI Reports French Agency for Safety of Health Products Has Cleared Patient Enrollment for Global Phase III Head, Neck Cancer Trial",2014-07-30 08:35:00-04:00,CVM,negative
320545.0,CEL-SCI Announces Co. Has Been Cleared to Begin Patient Enrollment in Phase 3 Multikine Study in Turkey,2014-07-23 08:09:00-04:00,CVM,positive
320546.0,CEL-SCI Receives Regulatory Clearance To Expand Phase III Head And Neck Cancer Trial Into Turkey,2014-07-22 08:35:00-04:00,CVM,negative
320547.0,CEL-SCI Announce Approval to Expand Phase III Trial,2014-07-22 08:31:00-04:00,CVM,positive
320548.0,CEL-SCI Announces Regulatory Clearance to Expand Phase III Head and Neck Cancer Trial In Austria,2014-07-08 08:15:00-04:00,CVM,negative
320549.0,CEL-SCI Announces 93% Surge in QoQ Patient Enrollment,2014-07-01 08:31:00-04:00,CVM,neutral
320550.0,"CEL-SCI Announces Approval for Expanded Immunotherapy Phase III Head, Neck Cancer Trial Into UK",2014-06-02 09:31:00-04:00,CVM,negative
320551.0,S-3 Filing from Cel Sci Corp Shows Registration for $75M Securities Shelf,2014-05-23 16:18:00-04:00,CVM,positive
320552.0,Cel-Sci Corporation Reports Q2 EPS of $(0.24) vs $(0.11) Est,2014-05-13 08:01:00-04:00,CVM,neutral
320553.0,CEL-SCI Reports Record Month in April for Patient Enrollment in Its Phase III Head and Neck Cancer Trial ,2014-05-01 08:03:00-04:00,CVM,negative
320554.0,CEL-SCI Receives $3M from Warrant Exercises ,2014-04-29 08:33:00-04:00,CVM,neutral
320555.0,Morning Market Losers ,2014-04-14 09:48:00-04:00,CVM,negative
320556.0,CEL-SCI Prices $10M Offering at $1.40/Share,2014-04-14 09:10:00-04:00,CVM,neutral
320557.0,"Cel Sci Withdraws Form S-3, Says Registration Was Filed in Error",2014-04-10 11:53:00-04:00,CVM,negative
320558.0,"Morning Gainers for Friday, March 14, 2014",2014-03-14 10:09:00-04:00,CVM,neutral
320559.0,CEL-SCI Shares Rise 11% Premarket; May be Attributed to Thursday Seeking Alpha Article ,2014-03-14 07:24:00-04:00,CVM,positive
320560.0,"Mid-Day Gainers Mar. 7, 2014: SKUL, SMSI, DLIA, BIG, CVM, KFY, GTAT",2014-03-07 11:26:00-05:00,CVM,positive
320561.0,"Morning Movers for Mar. 7, 2014: SKUL, DLIA, BIG, GTAT, CCRN, FL Moving Higher; NLNK, FEYE, SWY, FCEL Lower",2014-03-07 09:04:00-05:00,CVM,negative
320562.0,"CEL-SCI Wins Approval for Listing, Trading of Warrants from the NYSE MKT, Will Trade Under Symbol 'CVM WS'",2014-02-04 13:44:00-05:00,CVM,positive
320563.0,CEL-SCI Says Navy Okays Commencement of Co.'s Phase I Trial for Treatment of Anal   Warts in HIV/HPV Co-Infected Patients,2014-02-03 08:41:00-05:00,CVM,positive
320564.0,CEL-SCI Prices $3.0M Unit at $0.63/Unit,2013-12-19 09:21:00-05:00,CVM,neutral
320565.0,CEL-SCI Corporation Announces Proposed Public Offering of Common Stock and Warrants,2013-12-18 16:23:00-05:00,CVM,neutral
320566.0,CEL-SCI Warrants to Trade Under Ticker Symbol 'CSCIW',2013-12-09 12:44:00-05:00,CVM,neutral
320567.0,CEL-SCI Receives Bosnia and Herzegovina Approval to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer ,2013-12-05 08:10:00-05:00,CVM,negative
320568.0,CEL-SCI Receives Croatian Government Approval to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer ,2013-11-12 09:46:00-05:00,CVM,negative
320569.0,"CEL-SCI Wins Approval from Gov't of Crotia to Begin Phase III Trial for Multikine in Head, Neck Cancer",2013-11-12 09:46:00-05:00,CVM,positive
320570.0,"CEL-SCI, Ergomed Announce Co-Development, Profit Sharing Deal for Multikine in HIV/HPV",2013-10-15 08:03:00-04:00,CVM,positive
320571.0,Morning Market Losers ,2013-10-08 09:58:00-04:00,CVM,negative
320572.0,"CEL-SCI Prices $17.8M Offering of Stock, Warrants",2013-10-08 08:30:00-04:00,CVM,neutral
320573.0,CEL-SCI Corporation Announces Proposed Public Offering of Common Stock and Warrants ,2013-10-07 16:06:00-04:00,CVM,neutral
320574.0,CEL-SCI Reports CRADA with Naval Medical Center in San Diego,2013-10-07 09:44:00-04:00,CVM,neutral
320575.0,Cel-Sci Wins Extension from NYSE Mkt for Regaining Listing Compliance,2013-10-04 08:31:00-04:00,CVM,positive
320576.0,Cel-Sci Reports 1-for-10 Reverse Stock split,2013-09-20 08:00:00-04:00,CVM,neutral
320577.0,CEL-SCI Says NYSE MKT Approves Plan to Return Co. to Listing-Standards Compliance,2013-09-03 08:05:00-04:00,CVM,positive
320578.0,Cel-Sci Corporation Reports Q3 EPS of $(0.01) vs $(0.02) Est,2013-08-09 16:31:00-04:00,CVM,neutral
320579.0,"CEL-SCI and NIAID Publish Data Showing That CEL-SCI's LEAPS Technology Halted Progression of Lethal Influenza in Three Different Influenza Virus Strains, Including a Drug-Resistant and a 2009 Pandemic Flu Strain ",2013-07-25 08:05:00-04:00,CVM,negative
320580.0,"CEL-SCI Issues Update on Phase 3 Trial, Says Enough Patients Enrolled to Date",2013-04-23 08:10:00-04:00,CVM,neutral
320581.0,UPDATE: CEL-SCI Announces NIAID Collaborators Have Submitted Bird Flu Study for Publication to Scientific Journal ,2013-04-08 13:03:00-04:00,CVM,negative
320582.0,Hearing NIAID Bird Flu Study Submitted to Scientific Journal,2013-04-08 12:58:00-04:00,CVM,negative
320583.0,UPDATE: Taglich Brothers Initiates CEL-SCI Corporation at Speculative Buy on Multikine Outlook,2013-02-20 07:28:00-05:00,CVM,positive
320584.0,Taglich Brothers Initiates Coverage on Cel-Sci Corporation at Speculative Buy,2013-02-20 06:31:00-05:00,CVM,positive
320585.0,"Chardan Capital Initiates Coverage on Cel-Sci Corporation at Buy, Announces $0.90 PT",2013-02-13 17:56:00-05:00,CVM,neutral
320586.0,"Cel-Sci Corporation Reports Q1 EPS of $(0.02), Inline",2013-02-08 16:22:00-05:00,CVM,neutral
320587.0,"Laidlaw & Co. Initiates Coverage on Cel-Sci Corporation at Buy, Announces $0.75 PT",2013-01-14 17:06:00-05:00,CVM,neutral
320588.0,CEL-SCI to Raise $10.5M in Registered Direct Offering,2012-12-04 09:18:00-05:00,CVM,neutral
320589.0,CEL-SCI Corporation to Raise $10.5M in Registered Direct Offering  ,2012-12-04 09:16:00-05:00,CVM,neutral
320590.0,CEL-SCI Says Interim Review of Ongoing Phase 3 Trial Showed No safety Concerns,2012-10-22 10:01:00-04:00,CVM,positive
320591.0,McNicoll Lewis Vlak Suspends Coverage on CEL-SCI,2012-10-09 06:27:00-04:00,CVM,neutral
320592.0,UPDATE: Cel-Sci Says Investor Will Get Warrants for 12M Shares,2012-06-19 09:18:00-04:00,CVM,positive
320593.0,CEL-SCI Will Sell 16M Shares at $0.35,2012-06-19 09:15:00-04:00,CVM,positive
320594.0,Cel-Sci Says Phase III Clinical Trial Moving Forward,2012-05-10 16:12:00-04:00,CVM,neutral
320595.0,"Benzinga's Microcap Movers for Wednesday March 21, 2012",2012-03-22 07:50:00-04:00,CVM,neutral
320596.0,CEL-SCI Corporation Pays off Convertible Debenture   ,2012-03-06 09:02:00-05:00,CVM,neutral
320597.0,Two Biotechs That Continue to Attract Positive Attention From Investors,2012-02-01 08:50:00-05:00,CVM,positive
320598.0,CEL-SCI Corporation to Raise $5.76M in Registered Direct Offering   ,2012-01-26 09:15:00-05:00,CVM,neutral
320599.0,Scorecard and New Picks: Technical Value Fishing Under $5,2012-01-26 07:18:00-05:00,CVM,positive
320600.0,CEL-SCI Corporation Pops after Optimistic Phase 3 Tests,2012-01-23 08:25:00-05:00,CVM,positive
320601.0,Cel-SCI's Chart Shows Shares May be Getting Ready For the Next Leg Up,2012-01-23 07:49:00-05:00,CVM,positive
320602.0,CEL-SCI Corporation Releases Letter to Shareholders   ,2012-01-20 16:00:00-05:00,CVM,neutral
320603.0,San Francisco Health Care Conferences Provide Plenty of Buzz and Chatter,2012-01-13 06:26:00-05:00,CVM,positive
320604.0,CEL- SCI Corporation Authorizes Expansion of Phase III Clinical Trial to an Additional 4 European Countries   ,2011-12-27 08:45:00-05:00,CVM,neutral
320605.0,CEL- SCI Corporation Updates Positive Phase III Clinical Activities for Investigational Cancer Therapy Multikine ,2011-12-07 09:44:00-05:00,CVM,negative
320606.0,CEL- SCI Corporation Updates Phase III Clinical Activities for Investigational Cancer Therapy Multikine ,2011-11-02 08:46:00-04:00,CVM,negative
320607.0,CEL-SCI Corporation Announces the Closing of Its $4 Million Registered Direct Offering of Common Stock and Warrants   ,2011-10-07 09:00:00-04:00,CVM,neutral
320608.0,CEL-SCI Corporation to Raise $4 Million in Registered Direct Offering   ,2011-10-04 09:10:00-04:00,CVM,neutral
320609.0,"CEL-SCI Announces Exclusive Sales, Marketing and Distribution Agreement for Its Investigational Cancer Therapy Multikine for Argentina and Venezuela ",2011-08-23 10:16:00-04:00,CVM,negative
320610.0,CEL-SCI Addresses Warning Letter in Regard to Statements on Its Corporate Website ,2011-08-18 17:00:00-04:00,CVM,negative
320611.0,CEL-SCI Receives Key Chinese Patent for Its Investigational Cancer Therapy Multikine ,2011-08-17 09:35:00-04:00,CVM,negative
320612.0,CEL-SCI Corporation and Teva Pharmaceuticals Expand Licensing Agreement ,2011-07-19 10:54:00-04:00,CVM,positive
320613.0,"CEL-SCI Announces Start of Multikine Phase III Study by Teva Pharmaceuticals Industries, Ltd. in Israel ",2011-06-27 09:10:00-04:00,CVM,neutral
320614.0,CEL-SCI Corporation Announces Data Showing Cancer Drug Multikine Lowers Cholesterol in Clinical Studies ,2011-06-21 09:05:00-04:00,CVM,negative
320615.0,CEL-SCI Commences Phase III Clinical Trial in Head and Neck Cancer in Hungary ,2011-06-13 09:42:00-04:00,CVM,negative
320616.0,CEL-SCI Corporation Study Shows LEAPS Dendritic Cell Therapy to Be Effective in Treating H1N1 Virus ,2011-05-26 09:15:00-04:00,CVM,positive
320617.0,CEL-SCI Commences Phase III Clinical Trial in Head and Neck Cancer in Russia ,2011-05-19 10:09:00-04:00,CVM,negative
320618.0,CEL-SCI Commences Phase III Clinical Trial in Head and Neck Cancer in Canada ,2011-05-17 09:00:00-04:00,CVM,negative
320619.0,CEL-SCI Commences Phase III Clinical Trial in Head and Neck Cancer in Poland   ,2011-05-13 09:01:00-04:00,CVM,negative
320620.0,CEL-SCI Corporation Announces New Jersey Medical School and Veteran Affairs Medical Center is Ready to Commence Enrollment for Phase III Clinical Trial of Multikine in Head and Neck Cancer    ,2011-05-09 09:08:00-04:00,CVM,negative
320621.0,CEL-SCI Corporation Receives Government Approval in Poland to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer   ,2011-05-04 09:59:00-04:00,CVM,negative
320622.0,CEL-SCI Corporation Receives Final Government Approval from Taiwan to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer   ,2011-05-03 09:20:00-04:00,CVM,negative
320623.0,CEL-SCI Corporation Receives Final Canadian Government Approval to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer   ,2011-04-29 09:15:00-04:00,CVM,negative
320624.0,CEL-SCI Commences Phase III Clinical Trial in Head and Neck Cancer in India   ,2011-04-28 11:21:00-04:00,CVM,negative
320625.0,CEL-SCI Corporation Receives Government Approval in India to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer   ,2011-04-07 09:40:00-04:00,CVM,negative
320626.0,CEL-SCI Corporation Receives Israeli Government Approval to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer   ,2011-03-30 09:35:00-04:00,CVM,negative
320627.0,CEL-SCI Corporation Reports Q1 EPS of $0.03,2011-02-10 09:07:00-05:00,CVM,neutral
320628.0,"CEL-SCI Corp. (CVM) moving due to (AMGN) buying private company BIOVEX  in 1 billion dollar deal, same space as CVM in head and neck phase 3  , $1 billion dollar deal would value cvm @ $4 plus a share",2011-01-25 10:13:00-05:00,CVM,positive
320629.0,CEL-SCI Corporation Receives Russian Government Approval to Commence Phase III Clinical Trial   ,2011-01-05 09:45:00-05:00,CVM,positive
320630.0,Exclusive Interview: Cel-Sci CEO (CVM),2010-12-31 11:27:00-05:00,CVM,positive
320631.0,"Stocks To Watch For December 30 (UAL, ENDP, URZ, BX, CVM)",2010-12-30 03:13:00-05:00,CVM,neutral
320632.0,Cel-Sci Comments On Phase III (CVM),2010-12-29 12:48:00-05:00,CVM,neutral
320633.0,CEL-SCI Commences Phase III Clinical Trial,2010-12-29 07:30:00-05:00,CVM,neutral
320634.0,"CEL-SCI Corporation Receives $733,437 Grant ",2010-11-01 12:23:00-04:00,CVM,positive
320635.0,Eli Lilly Drug Fails Phase 3 Trial (LLY),2010-10-11 08:50:00-04:00,CVM,negative
320636.0,CEL-SCI Corporation Receives Approval from Hungary to Commence Phase III Clinical Trial,2010-10-05 09:01:00-04:00,CVM,positive
320637.0,Cel-Sci Corporation Running On Acquisition  Rumors ,2010-09-21 11:36:00-04:00,CVM,neutral
320638.0,Cel-Sci Corporation In Play This Morning (CVM),2010-08-17 08:51:00-04:00,CVM,positive
320639.0,"Amgen Phase III Immunotherapy Trials Fail; CVM Last Player On Deck This Year (AMGN, TEVA, DNDN, CVM)",2010-08-16 11:58:00-04:00,CVM,negative
320640.0,"Biggest Losers (CVM, SGEN, SCLN, FOLD, FTBK)",2009-10-05 12:24:00-04:00,CVM,negative
320641.0,CEL-SCI Corporation (CVM) Zooms 77% On Special Investigative Report,2009-09-15 14:07:00-04:00,CVM,positive
320642.0,"Today's Morning Top Gainers (FNET,LXRX,DIET,CLFD,MPG,CVM)",2009-09-15 12:16:00-04:00,CVM,positive
320643.0,"New 52-Week High Stocks – LXRX,CLFD,CVM,AAPL,CRUS",2009-09-15 11:42:00-04:00,CVM,neutral
320644.0,"WallStSense.com Fundamental & Technical Coverage of GNW, AOC, CMS, IFF, AHL and CVM",2009-08-17 06:52:00-04:00,CVM,neutral
320645.0,MPX Releases Its Results for the Second Quarter of 2009,2009-08-13 11:02:00-04:00,CVM,neutral
